- Home
- IMCR vs GTX Comparison
IMCR vs GTX Comparison
Compare IMCR & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- GTX
- Stock Information
- Founded
- IMCR 2008
- GTX 2018
- Country
- IMCR United Kingdom
- GTX Switzerland
- Employees
- IMCR N/A
- GTX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- GTX Auto Parts:O.E.M.
- Sector
- IMCR Health Care
- GTX Consumer Discretionary
- Exchange
- IMCR Nasdaq
- GTX Nasdaq
- Market Cap
- IMCR 1.5B
- GTX 2.0B
- IPO Year
- IMCR 2021
- GTX N/A
- Fundamental
- Price
- IMCR $31.15
- GTX $10.54
- Analyst Decision
- IMCR Buy
- GTX Strong Buy
- Analyst Count
- IMCR 10
- GTX 1
- Target Price
- IMCR $58.13
- GTX $14.00
- AVG Volume (30 Days)
- IMCR 473.9K
- GTX 3.0M
- Earning Date
- IMCR 08-07-2025
- GTX 07-24-2025
- Dividend Yield
- IMCR N/A
- GTX 2.28%
- EPS Growth
- IMCR N/A
- GTX N/A
- EPS
- IMCR N/A
- GTX 1.28
- Revenue
- IMCR $333,581,000.00
- GTX $3,438,000,000.00
- Revenue This Year
- IMCR $26.82
- GTX $1.06
- Revenue Next Year
- IMCR $8.15
- GTX $6.41
- P/E Ratio
- IMCR N/A
- GTX $8.18
- Revenue Growth
- IMCR 25.75
- GTX N/A
- 52 Week Low
- IMCR $23.15
- GTX $7.02
- 52 Week High
- IMCR $41.54
- GTX $12.09
- Technical
- Relative Strength Index (RSI)
- IMCR 44.46
- GTX 53.34
- Support Level
- IMCR $30.83
- GTX $9.57
- Resistance Level
- IMCR $37.56
- GTX $10.56
- Average True Range (ATR)
- IMCR 1.58
- GTX 0.29
- MACD
- IMCR -0.59
- GTX 0.01
- Stochastic Oscillator
- IMCR 15.64
- GTX 93.47
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.